- Home
- ZG vs GMAB Comparison
ZG vs GMAB Comparison
Compare ZG & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZG
- GMAB
- Stock Information
- Founded
- ZG 2004
- GMAB 1999
- Country
- ZG United States
- GMAB Denmark
- Employees
- ZG N/A
- GMAB N/A
- Industry
- ZG Business Services
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- ZG Consumer Discretionary
- GMAB Health Care
- Exchange
- ZG Nasdaq
- GMAB Nasdaq
- Market Cap
- ZG 20.9B
- GMAB 17.4B
- IPO Year
- ZG 2011
- GMAB N/A
- Fundamental
- Price
- ZG $68.43
- GMAB $30.32
- Analyst Decision
- ZG Buy
- GMAB Strong Buy
- Analyst Count
- ZG 31
- GMAB 6
- Target Price
- ZG $86.67
- GMAB $40.40
- AVG Volume (30 Days)
- ZG 640.1K
- GMAB 2.4M
- Earning Date
- ZG 10-30-2025
- GMAB 11-06-2025
- Dividend Yield
- ZG N/A
- GMAB N/A
- EPS Growth
- ZG N/A
- GMAB 132.41
- EPS
- ZG N/A
- GMAB 25.10
- Revenue
- ZG $2,483,000,000.00
- GMAB $3,845,670,022.00
- Revenue This Year
- ZG $17.58
- GMAB $24.92
- Revenue Next Year
- ZG $14.15
- GMAB $15.97
- P/E Ratio
- ZG N/A
- GMAB $1.20
- Revenue Growth
- ZG 15.17
- GMAB 29.57
- 52 Week Low
- ZG $56.63
- GMAB $17.24
- 52 Week High
- ZG $90.22
- GMAB $33.65
- Technical
- Relative Strength Index (RSI)
- ZG 40.09
- GMAB 55.17
- Support Level
- ZG $68.35
- GMAB $28.08
- Resistance Level
- ZG $72.10
- GMAB $30.78
- Average True Range (ATR)
- ZG 2.24
- GMAB 0.68
- MACD
- ZG -0.02
- GMAB 0.10
- Stochastic Oscillator
- ZG 26.23
- GMAB 79.44
About ZG Zillow Group Inc.
Zillow Group Inc is an Internet-based real estate company that offers its customers an on-demand experience for selling, buying, renting, or financing with transparency and ease The group works with real estate agents, brokers, builders, property managers, and landlords to pair technology with top-notch service. The group has brands such as Zillow, Trulia, StreetEasy, Hotpads, Zillow Rentals, Zillow Premier Agent and others.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.